Astellas Pharma Inc. Revises Consolidated Earnings Guidance for Fiscal Year 2025 Ending March 31, 2026

marketscreener
2025.10.30 11:25
portai
I'm PortAI, I can summarize articles.

Astellas Pharma Inc. revised consolidated earnings guidance for fiscal year 2025 ending March 31, 2026. For the year, the company now expects revenue of JPY 2,030,000 million against previous guidance of JPY 1,930,000 million, Operating profit of JPY 240,000 million against previous guidance of JPY 160,000 million, Profit for the year of JPY 180,000 million against previous guidance of JPY 130,000 million, and Basic earnings per share of JPY 100.50 per share against previous guidance of JPY 72.61.

Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.